Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Rahman 2021 Mol Biol Rep

From Bioblast
Revision as of 10:53, 27 December 2021 by Gnaiger Erich (talk | contribs) (Created page with "{{Publication |title=Rahman A, Tabassum T, Araf Y, Al Nahid A, Ullah MA, Hosen MJ (2021) Silent hypoxia in COVID-19: pathomechanism and possible management strategy. Mol Biol...")
(diff) ← Older revision | Latest revision (diff) | Newer revision β†’ (diff)
Publications in the MiPMap
Rahman A, Tabassum T, Araf Y, Al Nahid A, Ullah MA, Hosen MJ (2021) Silent hypoxia in COVID-19: pathomechanism and possible management strategy. Mol Biol Rep 48:3863-9. doi: 10.1007/s11033-021-06358-1

Β» PMID: 33891272 Open Access

Rahman A, Tabassum T, Araf Y, Al Nahid A, Ullah MA, Hosen MJ (2021) Mol Biol Rep

Abstract: The novel coronavirus disease 2019 (COVID-19) has become a severe health issue, especially to the patients who develop silent hypoxia condition after SARS-CoV-2 infection. Due to the lack of dyspnoea and extremely low oxygen saturation level, these patients are at exceptionally higher risk. Although the prevalence of silent hypoxia in COVID-19 patients has been evident in several cases, the underlying pathomechanism behind this condition is still unclear. Silent hypoxia in SARS-CoV-2 infected patients can be diagnosed with the help of a pulse oximeter, blood gas levels, and a 6-min walking test. While the clinicians and researchers figure out the exact reason for this phenomenon, the patients must be under strict day-to-day monitoring. In this article, we aim to provide comprehensive insights into the underlying symptoms, mechanism, and possible factors behind the occurrence of silent hypoxia among COVID-19 patients.

β€’ Bioblast editor: Gnaiger E


Labels: MiParea: Patients 

Stress:Hypoxia  Organism: Human 

Preparation: Intact organism